HRP20130042T1 - Postupci lijeäśenja reumatoidnog artritisa - Google Patents

Postupci lijeäśenja reumatoidnog artritisa Download PDF

Info

Publication number
HRP20130042T1
HRP20130042T1 HRP20130042AT HRP20130042T HRP20130042T1 HR P20130042 T1 HRP20130042 T1 HR P20130042T1 HR P20130042A T HRP20130042A T HR P20130042AT HR P20130042 T HRP20130042 T HR P20130042T HR P20130042 T1 HRP20130042 T1 HR P20130042T1
Authority
HR
Croatia
Prior art keywords
antibody
fragment
dose
use according
pharmaceutical composition
Prior art date
Application number
HRP20130042AT
Other languages
English (en)
Croatian (hr)
Inventor
Alan M. Solinger
Alexander Owyang
Original Assignee
Xoma Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd. filed Critical Xoma Technology Ltd.
Publication of HRP20130042T1 publication Critical patent/HRP20130042T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20130042AT 2008-06-06 2009-06-05 Postupci lijeäśenja reumatoidnog artritisa HRP20130042T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5971108P 2008-06-06 2008-06-06
US9523208P 2008-09-08 2008-09-08
PCT/US2009/046441 WO2009149370A1 (en) 2008-06-06 2009-06-05 Methods for the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
HRP20130042T1 true HRP20130042T1 (hr) 2013-03-31

Family

ID=40983388

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130042AT HRP20130042T1 (hr) 2008-06-06 2009-06-05 Postupci lijeäśenja reumatoidnog artritisa

Country Status (12)

Country Link
US (1) US20110189172A1 (https=)
EP (1) EP2293816B1 (https=)
JP (2) JP5607613B2 (https=)
AU (1) AU2009256072B2 (https=)
CA (1) CA2727171A1 (https=)
CY (1) CY1113640T1 (https=)
DK (1) DK2293816T3 (https=)
ES (1) ES2398693T3 (https=)
HR (1) HRP20130042T1 (https=)
PL (1) PL2293816T3 (https=)
PT (1) PT2293816E (https=)
WO (1) WO2009149370A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
AU2011296356B2 (en) 2010-09-03 2015-07-09 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
WO2013139701A1 (en) * 2012-03-19 2013-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm
CA2888583C (en) 2012-11-05 2022-03-29 Delenex Therapeutics Ag Binding members to il-1 beta
WO2014095808A1 (en) 2012-12-17 2014-06-26 Delenex Therapeutics Ag Antibodies against il-1 beta
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
CA2963606A1 (en) 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
AU2015345323A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use in ophthalmology
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US4762914A (en) * 1984-05-18 1988-08-09 Auron Philip E Truncated protein of interleukin-1
US5077219A (en) * 1984-05-18 1991-12-31 New England Medical Center Hospitals Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5122459A (en) * 1984-12-31 1992-06-16 Immunex Corporation Gene encoding biologically active human interleukin 1
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5474899A (en) * 1987-05-13 1995-12-12 Cistron Biotechnology, Inc. Selective immunoassay for IL-1 β
EP0364778B1 (en) * 1988-10-01 1996-03-13 Otsuka Pharmaceutical Co., Ltd. Antibody against interleukin-1beta
EP0460052B1 (en) * 1989-02-27 1998-04-15 New England Medical Center Il-1 biological activity inhibitors
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) * 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994000470A1 (en) * 1992-06-30 1994-01-06 The Wistar Institute Of Anatomy And Biology DEVELOPMENTAL EMBRYONIC MOUSE cDNA LIBRARIES
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20030166069A1 (en) * 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US6727234B2 (en) * 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
EP1423432A4 (en) * 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
US20050152850A1 (en) * 2004-01-09 2005-07-14 Engebretson Steven P. Methods and compositions for facilitating metabolic control
US7732478B2 (en) * 2004-01-09 2010-06-08 The Trustees Of Columbia University In The City Of New York Methods for facilitating metabolic control
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
DK1899378T3 (da) * 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
TR201802449T4 (tr) * 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
CA2673592C (en) * 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
US8637029B2 (en) * 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout

Also Published As

Publication number Publication date
PL2293816T3 (pl) 2013-04-30
JP2015007098A (ja) 2015-01-15
DK2293816T3 (da) 2013-02-04
ES2398693T3 (es) 2013-03-21
PT2293816E (pt) 2013-02-13
JP5607613B2 (ja) 2014-10-15
CA2727171A1 (en) 2009-12-10
US20110189172A1 (en) 2011-08-04
JP2011522832A (ja) 2011-08-04
AU2009256072B2 (en) 2015-05-28
WO2009149370A1 (en) 2009-12-10
CY1113640T1 (el) 2016-06-22
JP5809338B2 (ja) 2015-11-10
EP2293816A1 (en) 2011-03-16
AU2009256072A1 (en) 2009-12-10
EP2293816B1 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
HRP20130042T1 (hr) Postupci lijeäśenja reumatoidnog artritisa
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2015007098A5 (https=)
BG108514A (en) METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
IL252631B1 (en) ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
JP2011507891A5 (https=)
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2018100129A (ru) Способы лечения подагры
BRPI0412890A (pt) método de tratar uma doença em um indivìduo humano em necessidade do mesmo, composição farmacêutica, e, métodos de selecionar um composto para administração conjuntamente com um anticorpo terapêutico, e de aumentar a eficiência de um tratamento envolvendo a administração de um anticorpo terapêutico que pode ser ligado por cd16 em um indivìduo
RU2011144312A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
HRP20212028T1 (hr) Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
MXPA05007843A (es) Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes.
ME03797B (me) Stabilne formulacije koje sadrže anti-pcsk9 antitela
JP2014515763A5 (https=)
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
BRPI0413394A (pt) formulação de lantánio mastigável em tablete, formulação farmacêutica em tablete ou em pó, método para tratar hiperfosfatemia, uso de uma quantidade terapeuticamente efetiva de uma formulação de um composto de lantánio, processo para preparar uma formulação em tablete de um composto de lantánio
JP2011522832A5 (https=)
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EA201290172A1 (ru) Стабильные полипептиды, вариабельные домены антитела и антагонисты против tnfr1
JP2006508039A5 (https=)
MX363119B (es) Composicion farmaceutica.